|Bid||16.47 x 1800|
|Ask||16.63 x 1000|
|Day's Range||15.65 - 16.70|
|52 Week Range||13.11 - 18.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Just when we thought that COVID was starting to fade, the Delta variant has come our way. Is this the dreaded vaccine-resistant wave that will put economies back into lockdown? So far, at least, that doesn’t appear so – while this variant has shown the ability to infect people who are fully vaccinated, the vaccines have also shown efficacy in preventing serious illness, even from the Delta variant. What we’re looking at is an increase in cases, but a decrease in serious hospitalizations. Taking
The IPO market set another record amid a landmark quarter for Q2 2021, according to a report published by Renaissance Capital — 113 IPOs raised $39.9 billion in Q2, marking the “busiest quarter for IPOs in over two decades."
The companies are Verve Therapeutics, Lyell Immunopharma, iSpecimen, and Angel Oak Mortgage. Shares of Verve rocketed 68%.